Monday, February 20, 2017

Drugs in Clinical Pipeline: RO7062931 | Treatment of Chronic Hepatitis B Virus | Antivirals Agents

RO7062931 is a new experimental drug being developed by Roche pharma for treating patients with Chronic Hepatitis B. Hepatitis B is an infectious disease caused by the hepatitis B virus (HBV) which affects the liver. It can cause both acute and chronic infections. Many people have no symptoms during the initial infection. The virus is transmitted through contact with the blood or other body fluids of an infected person. An estimated 240 million people are chronically infected with hepatitis B (defined as hepatitis B surface antigen positive for at least 6 months). However, it can be prevented by currently available safe and effective vaccine.

Treatment of Chronic Hepatitis B Virus
New Drug for Treatment of Chronic Hepatitis B Virus

RO7062931 is administered subcutaneously and at present it is in Phase I clinical trials [1, 2].

1. Towards HBV Cure? Paris Hepatology Conference, 30-31st Jan 2017. (free article)
2. A Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of RO7062931in Healthy Volunteers and Subjects With Chronic Hepatitis B     Recruiting. NCT03038113
1 2 3